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Background: Mitochondrial dysfunction contributes to degenerative neurological disorders, consequently there
is a need for mitochondria-targeted therapies that are effective within the brain. One approach to deliver
pharmacophores is by conjugation to the lipophilic triphenylphosphonium (TPP) cation that accumulates in
mitochondria driven by the membrane potential. While this approach has delivered TPP-conjugated compounds
to the brain, the amounts taken up are lower than by other organs.
Methods: To discover why uptake of hydrophobic TPP compounds by the brain is relatively poor, we assessed the
role of the P-glycoprotein (Mdr1a/b) and breast cancer resistance protein (Bcrp) ATP binding cassette (ABC)
transporters, which drive the efﬂux of lipophilic compounds from the brain thereby restricting the uptake of
lipophilic drugs. We used a triple transgenic mouse model lacking two isoforms of P-glycoprotein (Mdr1a/1b)
and the Bcrp.
Results: There was a signiﬁcant increase in the uptake into the brain of two hydrophobic TPP compounds, MitoQ
and MitoF, in the triple transgenics following intra venous (IV) administration compared to control mice. Greater
amounts of the hydrophobic TPP compounds were also retained in the liver of transgenic mice compared to
controls. The uptake into the heart, white fat, muscle and kidneys was comparable between the transgenic
mice and controls.
Conclusion: Efﬂux of hydrophobic TPP compounds by ABC transporters contributes to their lowered uptake into
the brain and liver.
General signiﬁcance: These ﬁndings suggest that strategies to bypass ABC transporters in the BBB will enhance
delivery of mitochondria-targeted antioxidants, probes and pharmacophores to the brain.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial dysfunction contributes to a wide range of degener-
ative neurological disorders and to acute brain damage [1–4].
Consequently there is considerable interest in developing therapies
that decrease mitochondrial damage and preserve organelle func-
tion [1,3]. Mitochondria-targeted therapies based on lipophilic alkylteins; BBB, blood–brain barrier;
IP, intra peritoneal; IV, intra ve-
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l rights reserved.triphenylphosphonium (TPP) cations have been developed and show
promise in vivo and in human trials [1,5,6]. These TPP lipophilic cations
pass directly through phospholipid bilayers due to their large hydro-
phobic surface area lowering the activation energy for uptake [5,7,8],
while their positive charge causes their accumulation several-
hundred fold within mitochondria inside cells, driven by the plasma
and mitochondrial membrane potentials [5,7]. These properties have
been used to deliver a range of TPP cations selectively to mitochondria
within cells, including: antioxidants [5,9–11], thiol reagents [12,13],
spin traps [14–17], ﬂuorescent reactive oxygen species (ROS) probes
[18–21], toxins [22,23], DNA alkylating agents [24] and nitric oxide do-
nors [25]. One of these compounds, the mitochondria-targeted antiox-
idant mitoquinone (MitoQ), has shown efﬁcacy in a number of animal
models of pathologies [26–32]. Furthermore, MitoQ has been used in
humans and shown to be safe during long-term oral administration
[33] and to be effective at decreasing liver damage in a preliminary
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Fig. 1. Structures of the TPP cations investigated.
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targeted bioactive molecules based on TPP compounds have potential
as pharmaceuticals.
A number of animal studies have investigated the distribution of
TPP compounds in vivo and these investigations have shown that
the uptake of TPP compounds into most tissues was rapid and exten-
sive following long-term oral administration or acute intravenous
(IV) or intraperitoneal (IP) delivery [32,35,36]. However, while the
TPP compounds were taken up into the brain, the extent of uptake
was signiﬁcantly less than into other tissues [32,35,36]. Supporting
the uptake of TPP compounds by the brain, long-term administration
of MitoQ by intraperitoneal injection leads to protection against brain
mitochondrial damage in the MPTP animal model of Parkinson's dis-
ease [37]. Furthermore, oral delivery of MitoQ to the triple transgenic
Alzheimer's disease model also protected against oxidative damage
and memory impairment [38]. Therefore while TPP compounds are
taken up into the brain this uptake is signiﬁcantly less than by other
organs [35,36]. The rate and extent of uptake of TPP compounds
into cells and tissues is greatly enhanced by increasing the hydropho-
bicity of the molecule [36,39,40]. Increasing the hydrophobicity of
TPP compounds by incorporating a 10–11 methylene carbon chain
enhances the rate of uptake by lowering the activation energy for
movement across the plasma membrane and increases the extent of
accumulation within mitochondria by increasing adsorption to the
matrix-facing surface of the inner membrane [36,39,40]. However,
even for hydrophobic TPP cations such as MitoQ and MitoF uptake
by the brain was considerably lower than for other organs [36]. This
decreased uptake into the brain limits the potency of mitochondria-
targeted therapies and the usefulness of probes in the brain. There-
fore we set out to understand why the uptake of hydrophobic TPP
compounds by the brain is less than for other organs.
A major limitation to the uptake of lipophilic compounds into the
brain is the blood–brain barrier (BBB) [41,42]. The BBB comprises the
tightly sealed endothelial cells that form the lumen surface of the cap-
illaries perfusing the brain [41,42]. These endothelial cells contain
tight junctions, have minimal pinocytosis and very few cell fenestra-
tions so that they seal the brain capillaries [41,42], consequently com-
pounds that enter the brain have to pass through the endothelial cells
[41,42]. Restricting this passage are a series of ATP-binding cassette
(ABC) transporters that line the lumenal plasma membrane of the
endothelial cells and which pump lipophilic compounds out of the
cells, thereby limiting their uptake into the brain [41]. The action of
ABC-transporters in the BBB is a major factor limiting the delivery
of lipophilic drugs to the brain [42].
The archetypal ABC transporter involved in the BBB lipophilic
compound efﬂux is P-glycoprotein (P-gp, multi drug resistance 1
(Mdr1) protein and in humans as ABCB1), which uses ATP to drive
the efﬂux of lipophilic compounds across the plasma membrane and
out of cells [43]. The breast cancer resistance protein (Bcrp, ABCG2)
performs a similar function in the BBB [41]. Progress on the structure
and mechanism of P-gp suggests that BBB ABC-transporters act as
“hydrophobic vacuum cleaners” through a binding site within the
membrane that allows a wide range of lipophilic compounds to
enter the protein from the plasma membrane, followed by efﬂux
from the cell upon ATP hydrolysis [41,43–45]. P-gp is known to ac-
tively excrete lipophilic cations [41]. Furthermore, the uptake of
MitoQ into cells [46,47] and its excretion into the bile from the liver
in vivo are impeded by the action of P-gp [48]. Together these data
implicate the activity of ABC-transporters in the BBB as likely contrib-
utors to the relatively poor uptake of lipophilic TPP cations into the
brain.
Herewe set out to test the hypothesis that the lower uptake of hydro-
phobic TPP compounds into the brain is due to their excretion from BBB
endothelial cells by ABC-transporters such as P-gp. To assess this we
measured the acute uptake of the hydrophobic TPP cations MitoQ and
MitoF, and the more polar TPP cation methyltriphenylphosphonium(TPMP) (Fig. 1) into the brains of mice lacking the major ABC-
transporters. In mice there are two isoforms of P-gp, Mdr1a and Mdr1b
(also known as ABCB1a/1b) and a mouse model in which both of these
are deleted along with Brcp1 (ABCG2) has been developed [49]. The
Mdr1a/1b (−/−)(−/−) Brcp1 (−/−) mouse model has been used to
assess the contribution of BBB ABC-transporters to exclusion of lipophilic
compounds from the brain [50]. We found that the uptake of MitoQ and
MitoF into the brain was far greater in mice lacking these three
ABC-transporters, compared with control mice. These ﬁndings have
important implications for the development of mitochondria-speciﬁc
therapies and probes.
2. Materials and methods
2.1. Chemical syntheses
[3H] TPMP iodide (60 Ci/mmol) was from American Radiolabeled
Chemicals. [3H] MitoQ was synthesised and HPLC-puriﬁed to >97%
radiopurity, as described [39]. [3H] Fluoroundecyltriphenylphosphonium
(MitoF) was synthesised and puriﬁed as described previously [36]. The
published octan-1-ol/PBS partition coefﬁcients are as follows: TPMP,
0.35 [10]; MitoQ, 2760 [51]; MitoF, 740±100 [36].
2.2. Administration of compounds to mice
Mice lacking two isoforms of P-gp (ABCB1a and ABCB1b) and Bcrp1
(ABCG2) were created on the Friend leukaemia virus B strain (FVB)
background in the laboratory of Prof. Alfred Schinkel of the Netherlands
Cancer Institute [49] and female mice (Mdr1a/1b (−/−)(−/−)
Brcp1 (−/−)) lacking all three genes were supplied by Taconic
Farms (http://www.taconic.com) Model Number 3998-M (FVB.129P2-
Abcb1atm1Bor Abcb1btm1Bor Abcg2tm1Ahs N7). Mice were main-
tained on a 12 h light/dark cycle with ad libitum access to standard lab
chow and water for 8–16 weeks prior to experiments.
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on the uptake of MitoF, female C57/BL6 mice (~20 g) were used.
The mice were injected with CsA (Sandimmun, Novartis supplied as
50 mg/mL solution which was diluted 1:4 in sterile PBS and injected
100 μL at 50 mg/kg) IV by tail vein injection, or with PBS carrier,
followed 30 min later with [3H] MitoF (100 nmol) by IV tail vein
injection and 60 min later the mice were killed and the tissues
harvested. All procedures were approved by the University of Otago
animal ethics committee.
For injection themicewere placed in a restraining tube and injected
by the tail vein with 100 nmol [3H] compound (~400–500 nCi) in
100 μL sterile phosphate buffered saline (PBS) supplemented with
10% DMSO. A sample of the [3H] compound solution injected was
retained to calculate the speciﬁc activity, which was subsequently
used to determine the tissue contents of the compound. Two WT
mice and two transgenic mice were injected for each compound for
each time point. The total number of transgenic mice treated with
TPMP, MitoQ or MitoF were, 8, 8 and 10, respectively. The total num-
bers of WT mice treated with TPMP, MitoQ or MitoF were, 4, 6 and 8,
respectively. At the indicated times after injection, the mice were killedA
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100 nmol [3H] TPP compound by IV tail vein injection. At the indicated times the mice were
are in nmol/g wet weight tissue and are means±range for two separate WT mice and two s
brain/blood ratios of the three test compounds are shown at 1 h and 5 h post injection. Daby cervical dislocation and a blood sample of ~100–200 μL was
obtained by cardiac puncture. The organs were then removed, cleared
of blood by cutting into pieces and rinsing with saline, transferred to
pre-chilled Eppendorf tubes on ice, weighed and stored at −80 °C
until processing. The tissues taken were: heart, kidneys, liver, brain,
skeletal muscle (gastrocnemius) and white adipose tissue (subcutane-
ous). Injection of this amount of MitoQ and other TPP cations was
previously shown to be non-toxic [35], as was the case here. The
mice weremonitored after injection to ensure no pathology or distress.
2.3. Extraction of [3H] compounds from tissues
Tissues were thawed at room temperature and transferred to
50 mL Falcon tubes. Ice-cold methanol (~4 °C; 1 mL/100 mg tissue
wet weight) was added to the tissue and the tissue homogenised
using an Ultra Turrax homogeniser (2×30 s on ice). The homogenate
was transferred in 1 mL batches to 1.5 mL Eppendorf tubes and
centrifuged (10,000 ×g for 8 min at 4 °C). The methanol extract was
decanted into a 20 mL glass scintillation vial (Wheaton) and the
methanol evaporated under a stream of N2. Further ice-cold methanolype
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for 1 min, centrifuged as above and the methanol extract decanted to
a fresh 20 mL glass scintillation vial and evaporated. This procedure
was repeated 3 more times to give 5 extracts per tissue sample. The
amount of radioactivity in the ﬁfth extract was always negligible.
Scintillant (OptiPhase HiSafe II; 10 mL) was added to each vial, [3H]
DPM content measured in a scintillation counter (LKB Wallac 1217
Rackbeta) using appropriate quench corrections and the total amount
of radioactivity per sample calculated. The speciﬁc activity of the
injected [3H] compound was then used to calculate the tissue content
as mol compound/g wet weight tissue. The area under the curve
(AUC) for uptake of compounds into the brain were calculated from
the brain-time plots in Fig. 2 using the trapezoidal rule.
3. Results
3.1. Increased uptake of lipophilic TPP compounds into the brain of mice
lacking ABC-transporters
To determine whether the presence of ABC-transporters affected
the accumulation of TPP cations into the brain we compared the
amounts of MitoF, MitoQ and TPMP retained in the brain after admin-
istration (Fig. 2). To do this we injected a single bolus of 100 nmol
tritiated TPP compound IV into transgenic mice lacking the three
ABC transporters and compared the amount of radioactivity present
within the brain over 20 h (Fig. 2A–C). For MitoF (Fig. 2A) and
MitoQ (Fig. 2B), there was greater uptake into the brain in the trans-
genic compared to the wild type mice, in contrast, for TPMP there wasW
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Fig. 3. Time course of uptake of [3H] MitoF, [3H] MitoQ and [3H] TPMP into wild type and
100 nmol [3H] TPP compound by IV tail vein injection. At the indicated times the mice
compound/g wet weight tissue and are means±range for two separate WT mice and two
Fat, panels G–I.no difference (Fig. 2C). The area under the curve (AUC) for
MitoF accumulation into the brain from 1 to 48 h post injection
was 1.9 nmol·h/g wet weight for WT but increased ~9-fold to
16.6 nmol·h/g wet weight in the transgenic mice. Similarly, the AUC
for MitoQ accumulation into the brain from 1 to 20 h post injection
was 0.6 nmol·h/g wet weight for WT but increased ~4-fold to
2.3 nmol·h/g wet weight in the transgenic mice. In contrast, the
AUC for TPMP accumulation into the brain from 1 to 5 h post injection
was 0.87 nmol·h/g wet weight for WT and was unchanged at
0.84 nmol·h/g wet weight in the transgenic mice. The ratios of the
compounds in the brain relative to those in the blood 5 h after injec-
tion followed the same pattern with increased uptake of MitoF and
MitoQ in the transgenic mice, while the distribution of TPMP was
the same (Fig. 2D). This conﬁrmed that this difference was due to in-
creased accumulation of MitoF and MitoQ by the brain in the trans-
genic mice and not due to differences in plasma levels (Fig. 2D).
These data indicate that ABC-transporters decrease the extent of ac-
cumulation within the brain of the hydrophobic TPP compounds
MitoF and MitoQ, but not of the more polar TPMP.
3.2. ABC-transporters do not affect uptake of TPP compounds into the
heart, kidney or adipose tissue
To see if the absence of the ABC-transporters in other organs af-
fected the accumulation of TPP cations by other organs we assessed
the heart, kidney and white adipose tissue (Fig. 3A–I). As expected
from previous studies [36], there was extensive uptake of MitoF,
MitoQ and TPMP by the kidneys, less extensive uptake by the heartild type
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between the uptake into these three tissues between the wild
type and transgenic mice, indicating that the absence of the ABC-
transporters does not enhance their acute uptake of TPP cations.
3.3. Lack of ABC-transporters increases the accumulation of TPP
compounds by the liver
In contrast to the heart, kidney and adipose tissue, there was an
increase in the uptake of MitoF and MitoQ, but not of TPMP, in the
livers of the transgenic mice lacking the three ABC transporters com-
pared to controls (Fig. 4). This suggests that the ABC-transporters are
important in the excretion of the more hydrophobic TPP compounds
from the liver.
3.4. Absence of ABC-transporters does not affect blood levels of TPP
compounds
To see whether the ABC transporters altered the overall uptake of
TPP compounds from the circulation into tissues we next assessedMitoF
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Fig. 4. Time course of uptake of [3H] MitoF, [3H] MitoQ and [3H] TPMP into wild type and
transgenic mouse liver following IV injection. Mice were injected with a bolus of
100 nmol [3H] TPP compound by IV tail vein injection. At the indicated times the mice
were killed and the [3H] content in the liver was determined. Data are in nmol/g wet
weight tissue and are means±range for two separate WT mice and two separate trans-
genic mice per time point. MitoF, panel A; MitoQ, panel B; and TPMP, panel C.their levels in blood at various times following IV injection (Fig. 5A–
C). As expected, all three TPP compounds were rapidly cleared from
the blood after IV injection and there were no signiﬁcant differences
in the kinetics of clearance for the three compounds (Fig. 5A–C). There-
fore the action of the three ABC transporters does not markedly affect
the uptake into most tissues from the plasma of TPP compounds.
3.5. Effect of CsA on TPP cation uptake
The data so far suggest that the extent of accumulation of hydro-
phobic TPP cations into the brain and liver is decreased by the action
of the three ABC-transporters lacking in the transgenic mice. To see
if pharmacological inhibition the ABC-transporters could affect the
distribution of the compounds in potentially therapeutically useful
ways, we assessed the effect of CsA, an inhibitor of P-gp on the dis-
tribution of MitoF (Fig. 6A–B). The administration of CsA prior to the
IV injection of [3H] MitoF did not affect the uptake of MitoF into the
brain, muscle, fat, heart or kidney (Fig. 6A, B). However, CsA did in-
crease uptake into the liver suggesting that co-administration of
CsA may increase the content and thus the therapeutic efﬁcacy of
lipophilic alkyl TPP molecules in the liver, but not in the brain
(Fig. 6B).
4. Discussion
The lipophilic TPP cation is widely used to deliver a range of ther-
apeutic and probe molecules such as antioxidants to mitochondria in
vivo in animal models and in patients [5,26–28,31,33,34]. However,
uptake of these compounds into the brain is less than into other or-
gans. To assess why this is so here we have compared the accumula-
tion within the brain between wild type and transgenic mice lacking
three of the ABC-transporters that may contribute to exclusion of li-
pophilic cations in vivo. Here we have shown that the hydrophobic
TPP compounds MitoQ and MitoF are accumulated to a greater extent
by the brain in vivo in the transgenic mice following IV administra-
tion. This suggests that the action of the ABC transporters such as
P-gp in the BBB plays a signiﬁcant role in restricting the accumulation
of lipophilic TPP compounds by the brain. Therefore approaches that
can bypass this excretion pathway should lead to increased uptake
of TPP compounds into the brain and potentially enhance their ther-
apeutic potency for neurological disorders. However, administration
of the P-gp inhibitor CsA did not increase the brain uptake of MitoF,
even though it altered the liver uptake of MitoF [41,43], suggesting
that other modes to bypass the action of the ABC-transporters in the
BBB will be necessary to enhance the delivery of TPP compounds.
There were no major differences between the transgenic and wild
type mice in the uptake of MitoQ and MitoF in most other organs,
with the exception of the liver, where the uptake of MitoF and MitoQ
was greater in transgenic mice. Furthermore, the P-gp inhibitor CsA
also increased the levels of MitoF and MitoQ in the liver. Previously it
has been shown that a signiﬁcant proportion of the excretion of
MitoQ administered IV was through the liver by the biliary pathway,
with 25% of an IV MitoQ dose being excreted in this way within 4 h
[52]. This biliary excretion of MitoQwas inhibited by CsA [48]. Together
these data are consistent with hydrophobic TPP compounds being
excreted by the biliary pathway. The efﬁcacy of inhibition of P-gp and
related ABC transporters in the liver by CsA indicates that it is possible
to increase the levels of mitochondria-targeted compounds in the liver
by inhibiting this pathway.
The uptake of the TPP compounds by the kidney, heart and adi-
pose tissue was the same in the WT and transgenic mice, in contrast
to the brain and liver. As the three ABC transporters are relatively
poorly expressed in adipose tissue and the heart, the lack of an effect
of inactivating the transporters on alkyl TPP cation uptake into
these tissues is expected. However there is expression of the ABC
transporters in the kidney [53,54], consequently the absence of a
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uptake of lipophilic TPP cations is less clear. However, inactivation of
ABC transporters frequently has far greater effects on the brain up-
take of compounds compared to uptake into the kidney [55,56].
Therefore, our ﬁnding of a difference in uptake between the WT and
transgenic mice in the brain but not the kidney is consistent with
the literature. The mechanism remains obscure. One possibility is
that the dominant pathway(s) for the movement of lipophilic TPP
compounds into and out of the kidney cells occurs by pathways
distinct from those catalysed by the three ABC transporters. Another
possibility is that in the transgenic mice there is a compensatory
increase in the activity of other pathways that transport lipophilic
cations. This occurs in the Bcrp (−/−) mouse where the compensato-
ry upregulation of two sterol transporter genes, Abcg8 and Abcg5,
compensates for the lack of Bcrp [54]. Therefore, we cannot exclude
the possibility that in the normal kidney the three ABC transporters
investigated here are actually important in the disposition of lipophil-
ic TPP cations but that their loss is compensated for by expression of
other transporters. We emphasise that the lack of an effect of alkylM
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these ABC transporters contributes to the exclusion of alkyl TPP
cations by the BBB.
There were clear differences in the interaction with the ABC trans-
porters that depended on the hydrophobicity of the tracer alkyl TPP
compounds tested. For the two hydrophobic TPP compounds, MitoQ
and MitoF, distribution in the brain and liver was dramatically in-
creased by altering the activity of the ABC-transporters. In contrast,
the distribution of the more polar TPMP was unaffected by the pres-
ence or absence of ABC-transporters. This lack of effect on TPMP is
consistent with reported ﬁndings for the tetraphenylphosphonium
cation, which is of similar hydrophilicity to TPMP: ablation of the
two P-gp isoforms Mdr1a and Mdr1b in mice did not increase the up-
take of the tetraphenylphosphonium cation across the BBB [57]. One
interpretation of these ﬁndings is that the increased hydrophobicity
of the TPP compounds MitoQ and MitoF increases adsorption to the
cytosolic facing surface of the plasma membrane of the endothelial
cells and thus increases their access to the hydrophobic binding siteM
ito
F 
(nm
ol/
g)
B
30
20
40
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0
Heart Liver Kidney
Control
nce of CsA. Mice were pretreated with CsA (50 mg/kg) and 30 min later were injected
killed and the [3H] content in the brain, heart, muscle, fat, kidney and liver was deter-
wet weight tissue and are means±range for two separate WT mice and two separate
3464 C.M. Porteous et al. / Biochimica et Biophysica Acta 1830 (2013) 3458–3465of the ABC transporters and thereby enhances their efﬂux from the
cell. For more polar compounds, such as TPMP, their relatively low
hydrophobicity makes them poorer substrates for the ABC trans-
porters and consequently we did not see any effect of ablation of
the transporters on the distribution of TPMP in the brain or liver. It
is also likely that the afﬁnity of the hydrophobic TPP compounds for
the ABC transporters is greater than for more hydrophilic compounds.
Thus, increased hydrophobicity increases the rate and extent of up-
take into tissues in vivo [36,39]. However, the increased hydrophobic-
ity also increases the adsorption to the plasma membrane and access
to, and afﬁnity for, the binding site of the ABC transporters and conse-
quently increased excretion through the liver and decreased uptake
through the BBB. Therefore to enhance uptake into the brain it is
necessary to both increase hydrophobicity while avoiding excretion
by the ABC transporters.
To conclude, there are a number of possible reasons for relative
differences in the rate and extent of uptake of a TPP cation into an
organ. These include the extent of perfusion of the organ, the possibil-
ity that other organs have extracted most of the compound before it
arrives and the magnitudes of the plasma and mitochondrial
membrane potentials. However it is clear that the action of ABC
transporters in the BBB decreases the accumulation of hydrophobic
TPP cations into the brain and that overcoming this action of the
BBB would signiﬁcantly improve the targeting of therapeutic mole-
cules and probe molecules to mitochondria in the brain in vivo.
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